Kumar Pawan, Tyagi Rohit, Das Gobardhan, Bhaskar Sangeeta
National Institute of Immunology, New Delhi, India.
Immunology. 2014 Oct;143(2):258-68. doi: 10.1111/imm.12306.
Mycobacterium indicus pranii (MIP) is an atypical mycobacterial species possessing strong immunomodulatory properties. It is a potent vaccine candidate against tuberculosis, promotes Th1 immune response and protects mice from tumours. In previous studies, we demonstrated higher protective efficacy of MIP against experimental tuberculosis as compared with bacillus Calmette-Guérin (BCG). Since macrophages play an important role in the pathology of mycobacterial diseases and cancer, in the present study, we evaluated the MIP in live and killed form for macrophage activation potential, compared it with BCG and investigated the underlying mechanisms. High levels of tumour necrosis factor-α, interleukin-12p40 (IL-12p40), IL-6 and nitric oxide were produced by MIP-stimulated macrophages as compared with BCG-stimulated macrophages. Prominent up-regulation of co-stimulatory molecules CD40, CD80 and CD86 was also observed in response to MIP. Loss of response in MyD88-deficient macrophages showed that both MIP and BCG activate the macrophages in a MyD88-dependent manner. MyD88 signalling pathway culminates in nuclear factor-κB/activator protein-1 (NF-κB/AP-1) activation and higher activation of NF-κB/AP-1 was observed in response to MIP. With the help of pharmacological inhibitors and Toll-like receptor (TLR) -deficient macrophages, we observed the role of TLR2, TLR4 and intracellular TLRs in MIP-mediated macrophage activation. Stimulation of HEK293 cells expressing TLR2 in homodimeric or heterodimeric form showed that MIP has a distinctly higher level of TLR2 agonist activity compared with BCG. Further experiments suggested that TLR2 ligands are well exposed in MIP whereas they are obscured in BCG. Our findings establish the higher macrophage activation potential of MIP compared with BCG and delineate the underlying mechanism.
印度斯坦分枝杆菌(MIP)是一种具有强大免疫调节特性的非典型分枝杆菌物种。它是一种抗结核病的有力疫苗候选物,可促进Th1免疫反应并保护小鼠免受肿瘤侵害。在先前的研究中,我们证明与卡介苗(BCG)相比,MIP对实验性结核病具有更高的保护效力。由于巨噬细胞在分枝杆菌疾病和癌症的病理过程中起重要作用,因此在本研究中,我们评估了活的和灭活形式的MIP对巨噬细胞的激活潜力,将其与BCG进行比较并研究其潜在机制。与BCG刺激的巨噬细胞相比,MIP刺激的巨噬细胞产生了高水平的肿瘤坏死因子-α、白细胞介素-12p40(IL-12p40)、IL-6和一氧化氮。在对MIP的反应中,还观察到共刺激分子CD40、CD80和CD86的显著上调。MyD88缺陷型巨噬细胞反应丧失表明,MIP和BCG均以MyD88依赖性方式激活巨噬细胞。MyD88信号通路最终导致核因子-κB/激活蛋白-1(NF-κB/AP-1)激活,并且在对MIP的反应中观察到NF-κB/AP-1的更高激活。借助药理学抑制剂和Toll样受体(TLR)缺陷型巨噬细胞,我们观察到TLR2、TLR4和细胞内TLR在MIP介导的巨噬细胞激活中的作用。刺激以同型二聚体或异型二聚体形式表达TLR2的HEK293细胞表明,与BCG相比,MIP具有明显更高水平的TLR2激动剂活性。进一步的实验表明,TLR2配体在MIP中暴露良好,而在BCG中则被掩盖。我们的研究结果证实了MIP与BCG相比具有更高的巨噬细胞激活潜力,并阐明了其潜在机制。